# US 2017/0285043 A1 · METHODS OF IDENTIFYING MODULATORS OF SESTRIN-GATOR-2 INTERACTION AND USE OF SAME TO MODULATE mTORC1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0285043 A1
- Document ID: US20170285043A1
- Status: Published application
- Kind: A1
- Application number: 15/511,007
- Filed: 2015-09-11
- Published: 2017-10-05
- Earliest claimed: 2014-09-12
- Assignees: Whitehead Institute for Biomedical Research
- Applicants: Whitehead Institute for Biomedical Research
- Inventors: David M. Sabatini; Lynne Chantranupong; Rachel L. Wolfson; Jose Orozco; Robert A. Saxton; Shomit Sengupta
- Web page: https://patentgrep.com/patent/US20170285043A1

## CPC

- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- G01N 33/5041: {involving analysis of members of signalling pathways}
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides methods of identifying modulators of mTORC1 based upon their effect on GATOR2-Sestrin binding or Sestrin-leucine binding; and the use of such modulators to alter mTORC1 activity in a cell and to treat disease and conditions that are effected by mTORC1 activity.

## Claims

### Claim 1

A method of identifying a test compound as an activator of mTORC1 activity comprising the steps of:
a) providing a mixture comprising:
(i) a first polypeptide comprising the amino acid sequence of: a GATOR2-binding fragment of Sestrin1 (SEQ ID NO:1), Sestrin2 (SEQ ID NO:2), Sestrin3 (SEQ ID NO:3), or a polypeptide having at least 80% homology to any one of SEQ ID NOs:1-3 that retains the ability to bind GATOR2; and
(ii) a second polypeptide or protein complex comprising the amino acid sequence of: a Sestrin-binding fragment of a GATOR2 complex (SEQ ID NOs:4-8), or a polypeptide or protein complex having at least 80% homology to SEQ ID NOs:4-8 that retains the ability to bind to at least one of Sestrin1, Sestrin2 or Sestrin3,
under conditions that allow the first polypeptide to associate with the second polypeptide or protein complex;
b) incubating the mixture of a) with the test compound;
c) determining whether the amount of the first polypeptide associated with the second polypeptide or protein complex is altered in the presence of the test compound as compared to either the absence of the test compound or the presence of a negative control, wherein if the amount of association is decreased the test compound is identified as an activator of mTORC1 activity.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first polypeptide comprises the amino acid sequence of a GATOR2-binding fragment of any of Sestrin1 (SEQ ID NO:1), Sestrin2 (SEQ ID NO:2), Sestrin3 (SEQ ID NO:3), or SEQ ID NOs:9-11.

### Claim 3 (depends on 1)

The method of claim 1, wherein the second polypeptide or protein complex comprises the amino acid sequence of a Sestrin-binding fragment of a GATOR2 complex (SEQ ID NOs:4-8).

### Claim 4 (depends on 3)

The method of claim 3, wherein the second polypeptide or protein complex comprises the amino acid sequence of a Sestrin-binding fragment of WDR24 (SEQ ID NO:4).

### Claim at position 5

-16. (canceled)

### Claim 17

A method of identifying a test compound as an inhibitor of mTORC1 activity comprising the steps of:
a) providing a mixture comprising:
(i) a first polypeptide comprising the amino acid sequence of: a GATOR2-binding fragment of Sestrin1 (SEQ ID NO:1), Sestrin2 (SEQ ID NO:2), Sestrin3 (SEQ ID NO:3), or a polypeptide having at least 80% homology to any one of SEQ ID NOs:1-3 that retains the ability to bind GATOR2; and
(ii) a second polypeptide or protein complex comprising the amino acid sequence of: a Sestrin-binding fragment of a GATOR2 complex (SEQ ID NOs:4-8), or a polypeptide or protein complex having at least 80% homology to SEQ ID NOs:4-8 that retains the ability to bind to at least one of Sestrin1, Sestrin2 or Sestrin3,
under conditions that prevent the first polypeptide from associating with the second polypeptide or protein complex;
b) incubating the mixture of a) with the test compound;
c) determining whether the amount of the first polypeptide associated with the second polypeptide or protein complex is altered in the presence of the test compound as compared to either the absence of the test compound or the presence of a negative control, wherein if the amount of association is increased the test compound is identified as an inhibitor of mTORC1 activity.

### Claim 18 (depends on 17)

The method of claim 17, wherein the conditions that prevent the first polypeptide from associating with the second polypeptide or protein complex comprises the presence of leucine.

### Claim 19 (depends on 17)

The method of claim 17, wherein the first polypeptide comprises the amino acid sequence of a GATOR2-binding fragment of any of Sestrin1 (SEQ ID NO:1), Sestrin2 (SEQ ID NO:2), Sestrin3 (SEQ ID NO:3), or SEQ ID NOs:9-11.

### Claim at position 9

-33. (canceled)

### Claim 34

A method of modulating mTORC1 activity in a cell by contacting the cell with an agent that alters the interaction of a Sestrin with the GATOR2 complex as compared to a control.

### Claim at position 11

-37. (canceled)

### Claim 38

A method of identifying a test compound as a modulator of mTORC1 by determining if the test compound can induce or increase the affinity of Sestrin1 or Sestrin2 for leucine comprising the steps of:
a. providing a mixture comprising:
i. a polypeptide comprising the amino acid sequence of: a leucine binding fragment of Sestrin1 (SEQ ID NO:1) or Sestrin2 (SEQ ID NO:2), or a polypeptide having at least 80% homology to any one of SEQ ID NOS:1-2 that retains the ability to bind leucine; and
ii. leucine; and
iii. the test compound,
under conditions that allow leucine to bind to the polypeptide;
and
b. determining whether the amount of leucine bound to the polypeptide associated is altered in the presence of the test compound as compared to either the absence of the test compound or the presence of a negative control, wherein if the amount of binding is decreased in the presence of test compound, the test compound is identified as an inhibitor of mTORC1 activity; and if the amount of binding is increased in the presence of the test compound, the test compound is identified as an activator of mTORC1 activity.

### Claim 39

(canceled)

### Claim 40 (depends on 38)

The method of claim 38, wherein the leucine is tagged with a detectable label.

### Claim 41 (depends on 40)

The method of claim 40, wherein the leucine is tagged with a radiolabel.

### Claim at position 16

-49. (canceled)
